TNXP | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 4%

Liquidity 50%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-32.65%

1 Month

-59.48%

3 Months

-95.79%

6 Months

-98.09%

1 Year

-99.24%

2 Year

-99.89%

Key data

Stock price

$0.23

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$0.22 - $30.40

52 WEEK CHANGE

-$0.99

MARKET CAP

5.039 M

YIELD

N/A

SHARES OUTSTANDING

22.004 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$46,432,509

AVERAGE 30 VOLUME

$37,658,945

Company detail

CEO: Seth Lederman
Region: US
Website: https://www.tonixpharma.com/
Employees: 98
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

TNXP - Tonix Pharmaceuticals Holding Corp